Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft

PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate

PharmaEssentia Included in FTSE Russell Indices

PharmaEssentia and MPN Advocacy & Education International Launch New Educational Initiative to Empower People Living with Polycythemia Vera (PV)

New Study Demonstrates ropeginterferon alfa-2b-njft is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera

PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America

NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera

PharmaEssentia Initiates Phase 3b Trial of ropeginterferon alfa-2b-njft Investigating New Dosing Regimen for Patients with Polycythemia Vera (PV)

PharmaEssentia Corporation Announces Closing of Global Depositary Receipt Offering, Generating US$462.7M to Support Growth Plans and Pipeline Development